Macimorelin is a medication used to treat adult growth hormone deficiency. More specifically, macimorelin is a peptidomimetic growth hormone secretagogue (GHS) that acts as an agonist of GH secretagogue receptor, or ghrelin receptor (GHS-R1a) to dose-dependently increase GH levels.
- Mechanism
- Curator reviewed
Ghrelin is an endogenous ligand for the GH secretagogue receptor that is also called the ghrelin receptor (GHS-R1a). Upon activation of the receptor, ghrelin serves to increase growth hormone (GH) secretion. Macimorelin mimics the actions of ghrelin by stimulating GH release. As a synthetic agonist, it activates growth hormone secretagogue receptors present in the pituitary and hypothalamus.
- Primary indication
- Indicated for the diagnosis of adult growth hormone deficiency (AGHD).Curator reviewed · 1 structured indication
- Formula / weight
- C26H30N6O3 · 474.565 g/mol (avg)
- First approval
- United States, 2018 · European Union, 2021
- Code names
- AEZS-130 · ARD-07 · D-87575 · EP-01572 · EP-1572 · JMV-1843
- Brand names
Resolves to
UJVDJAPJQWZRFR-DHIUTWEWSA-NSMILESCC(C)(N)C(=O)N[C@H](CC1=CNC2=CC=CC=C12)C(=O)N[C@H](CC1=CNC2=CC=CC=C12)NC=OWhat you can answer from here — as of September 13, 2026
Which drugs share a target with Macimorelin, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account